LY2603618(IC-83) |cas 911222-45-2| DC Chem|Supplier|Price|Buy  

LY2603618(IC-83) |cas 911222-45-2| DC Chem|Supplier|Price|Buy

DC Chemicals Supply: LY2603618(IC-83) |cas 911222-45-2,Purity: >98% ,Cat No. DC7103, In stock.

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642572；

LY2603618(IC-83) |cas 911222-45-2 ,Synonym: IC-83; LY 2603618; LY-2603618  ,Chemical name: (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea ,Molecular Formula: C18H22BrN5O3 ,MW:436.3

LY2603618(IC-83) , cas 911222-45-2,Purity: >98%, Best Price and quality from DC Chemicals. LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials.

Chk1 is an ATP-dependent serine-threonine kinase and a key component in the DNA replication-monitoring checkpoint system activated by double-stranded breaks (DSBs). Chk1 contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. By inhibiting the activity of chk1, LY2603618 prevents the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. However, preclinical data involving LY2603618 has not been published until now. [1] Inhibition of Chk1 is predicted to enhance the effects of antimetabolites, such as gemcitabine. [2] LY2603618 treatment impairs DNA synthesis, increases DNA damage (via mitotic defects), induces apoptosis, and has synergistic activity with pemetrexed, especially in p53 mutant tumor cells. [3] In xenograft models, LY2603618 delays tumor growth when given in combination with pemetrexed. [3]